Should You Buy Rxsight Inc (RXST) Today? Analysis, Price Targets, and 2026 Outlook.
Conclusion
Hold
Latest Price
8.690
1 Day change
-2.47%
52 Week Range
34.710
Analysis Updated At
2026/01/30
RXST is not a good buy right now for an impatient buyer looking for immediate upside. The stock is in a strong downtrend (bearish moving-average stack and worsening MACD), just slipped below a key support zone (~8.75), and there are no near-term news catalysts or strong proprietary buy signals to justify stepping in today. While RSI is deeply oversold (bounce potential) and options positioning is skewed bullish, the tape is still bearish and the risk of further downside toward ~8.36 support is high.
**Intellectia Proprietary Trading Signals**
- [AI Stock Picker](module://ai_stock_pick): No signal on given stock today.
- [SwingMax](module://swingmax): No signal on given stock recently.
Technical Analysis
Trend is bearish: SMA_200 > SMA_20 > SMA_5 confirms a sustained downtrend. Momentum is weakening further with MACD histogram at -0.0699 and negatively expanding (bearish momentum increasing). RSI_6 at ~19.2 is deeply oversold, which can fuel short-term mean-reversion bounces, but oversold alone is not a buy trigger when MACD is still deteriorating.
Key levels: Pivot ~9.371 (major reclaim level). Near-term resistance: 9.99 then 10.38. Support: S1 ~8.749 (price 8.68 is below this, a bearish sign), next S2 ~8.364.
Pattern-based projection provided: ~50% chance of +1.25% next day, roughly flat next week (-0.02%), and stronger 1-month upside potential (+24.31%)—but the current setup suggests that upside is more likely after a confirmed base/reclaim above ~8.75–9.37 rather than immediately.
Options Data
Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio
Open interest is call-heavy (put/call OI 0.23), which is a bullish sentiment signal. However, actual trading activity is thin (today’s total volume 10 contracts; put volume 0), so sentiment is not strongly confirmed by active positioning.
Volatility: IV30 ~52.36 vs historical vol ~61.07, and IV percentile ~8.84 (IV rank ~7.08) indicates relatively cheap options vs recent history—often seen after selloffs. This can support upside trades structurally, but it does not override the current bearish price trend.
Technical Summary
Sell
10
Buy
3
Positive Catalysts
RSI is extremely oversold (~19), increasing odds of a short-term relief bounce if selling pressure fades.
Options open interest is strongly skewed to calls (bullish tilt).
Q3 gross margin improved materially to ~79.85% (+11.80% YoY), and net loss/EPS improved YoY (loss narrowing), indicating operational efficiency gains.
Analyst price targets cluster above the current price (roughly $9–$11), implying upside if growth stabilizes.
Neutral/Negative Catalysts
Technical trend remains decisively bearish (bearish MA stack + worsening MACD), and price is below S1 support (~8.75), raising odds of continuation down toward ~8.
No recent news/event catalyst in the last week to trigger an immediate rerating.
Financial Performance
Latest reported quarter: 2025/Q3. Revenue declined to $30.34M (-14.09% YoY), signaling weakening top-line momentum. Profitability metrics improved: net income increased to -$9.816M (loss narrowed, +54.88% YoY improvement), EPS improved to -$0.24 (+50% YoY improvement), and gross margin rose to ~79.85% (+11.80% YoY). Overall: improving efficiency/margins, but the market will likely require a return to sustained revenue growth before rewarding the stock.
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
Recent Street tone is cautious/neutral with modestly higher targets:
- 2026-01-30 William Blair initiated at Market Perform (no PT), explicitly citing stalled 2025 sales and wanting proof the engagement/turnaround is sustainable.
- 2026-01-20 Piper Sandler: Neutral, PT raised to $11 (from $10).
- 2025-12-02 Morgan Stanley: Equal Weight, PT raised to $10 (from $9).
- 2025-11-06 Stifel: Hold, PT raised to $10 (from $8).
- 2025-11-06 JPMorgan: Underweight, PT raised to $9 (from $8), still skeptical on growth outlook.
Wall Street pros: margin improvement, valuation discount vs peers, and potential for stabilization into 2026. Cons: uncertain re-acceleration of demand and credibility of a growth turnaround after 2025 stalling. Net: cautious/neutral consensus rather than a clear buy call.
Wall Street analysts forecast RXST stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RXST is 10.25 USD with a low forecast of 8 USD and a high forecast of 14 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
9 Analyst Rating
Wall Street analysts forecast RXST stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RXST is 10.25 USD with a low forecast of 8 USD and a high forecast of 14 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
6 Hold
2 Sell
Hold
Current: 8.910
Low
8
Averages
10.25
High
14
Current: 8.910
Low
8
Averages
10.25
High
14
William Blair
Market Perform
initiated
AI Analysis
2026-01-30
New
Reason
William Blair
Price Target
AI Analysis
2026-01-30
New
initiated
Market Perform
Reason
William Blair initiated coverage of RxSight with a Market Perform rating and no price target. The firm says that following "robust" growth in 2021-2024 led by early adopters to its adjustable intraocular lens, RxSight's sales stalled in 2025. While the stock trades at a "sizable discount" to peers, William Blair wants evidence that the company's new customer engagement efforts can sustainably turn around its performance before recommending the stock, the analyst tells investors in a research note.
Piper Sandler
Neutral
maintain
$10 -> $11
2026-01-20
Reason
Piper Sandler
Price Target
$10 -> $11
2026-01-20
maintain
Neutral
Reason
Piper Sandler raised the firm's price target on RxSight to $11 from $10 and keeps a Neutral rating on the shares. The firm is updating a handful of its models to adjust for preliminary Q4 results and initial full year 2026 guidance announcements from this past week or so.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for RXST
